Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/perindopril - Servier

Drug Profile

Amlodipine/perindopril - Servier

Alternative Names: Acerycal; Amlodipine/perindopril; Bi-Prestarium; Calcertil; Co-Prestarium; Coveram; Covercard; Covercor; Coverlam; Coversical; Coversyl AM; Perindopril arginine/amlodipine besylate; Perindopril/amlodipine; Prestalia; Prestance; Prestarium-Co; Presteram; Prexanor; Proacertil; Procoversyl; Reaptan; S-05985; Viacoram

Latest Information Update: 11 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servier
  • Developer Servier; Symplmed
  • Class Antihypertensives; Dihydropyridines; Indoles; Small molecules; Vascular disorder therapies
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Coronary artery disease; Hypertension

Most Recent Events

  • 04 Jan 2021 Adhera Therapeutics terminates its licence for Perindopril/amlodipine in USA
  • 14 Apr 2020 Perindopril/amlodipine - Servier is available for licensing in USA as of 31 Dec 2019. https://adherathera.com/
  • 28 Jan 2019 Launched for Hypertension (Treatment-naive) in Canada, prior January 2019 (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top